Understanding the costs and cost-effectiveness of TB treatment in Bangladesh

Location

Bangladesh, Bangladesh

Dates

01/01/2013 - 07/01/2015

PI

David Dowdy, MD, PhD, ScM

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are using these results to construct models of the cost-effectiveness of novel shorter-course regimens for drug-susceptible TB.

People

Eric Nuermberger, MD
Faculty
Richard Chaisson, MD
Director
Larry Moulton, PhD
Faculty
William R. Bishai, MD, PhD
Co-Director
Matt Murrill
Students

Projects

Human-centered Design and Communities of...

The goal of this project is to use local communities of practice and the emerging technique of human-centered design to improve...

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More

Scale-up and implementation of TB diagnostics...

We are evaluating the implementation, cost-effectiveness, and potential epidemiological impact of scaling up Xpert across 19...

Read More

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

ACTG 5279: Phase III Clinical Trial of...

Read More